PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34167562-8	2021	We also observed strong synergy between MRK-560 and KPT-8602 (eltanexor) in all NOTCH1-dependent T-ALL cell lines.	Eltanexor	62-71	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	40-43
34165175-5	2021	The aim of the present study was to evaluate the combination of CAR T cells with the SINE compounds eltanexor and selinexor.	Eltanexor	100-109	nuclear receptor subfamily 1 group I member 3	Homo sapiens	64-67
34165175-6	2021	As expected, eltanexor and selinexor were toxic to CD19-positive malignant cells and the sensitivity of cells towards SINEs correlated with the levels of XPO1-expression in ALL cell lines.	Eltanexor	13-22	CD19 molecule	Homo sapiens	51-55
34165175-6	2021	As expected, eltanexor and selinexor were toxic to CD19-positive malignant cells and the sensitivity of cells towards SINEs correlated with the levels of XPO1-expression in ALL cell lines.	Eltanexor	13-22	exportin 1	Homo sapiens	154-158
34165175-9	2021	Due to CAR T-cell toxicity, sequential use of SINEs and CAR T cells was evaluated: Cytotoxicity of CAR T cells increased significantly when target cells were pre-treated with the SINE compound eltanexor.	Eltanexor	193-202	nuclear receptor subfamily 1 group I member 3	Homo sapiens	56-59
34165175-10	2021	In addition, exhaustion of CAR T cells decreased when target cells were pre-treated with eltanexor.	Eltanexor	89-98	nuclear receptor subfamily 1 group I member 3	Homo sapiens	27-30
34167562-4	2021	In this study, we developed combination treatment strategies with the PSEN1-selective gamma-secretase inhibitor MRK-560 and other targeted agents (kinase inhibitors ruxolitinib and imatinib; XPO-1 inhibitor KPT-8602/eltanexor) for the treatment of T-ALL.	Eltanexor	207-215	exportin 1	Homo sapiens	191-196
34167562-8	2021	We also observed strong synergy between MRK-560 and KPT-8602 (eltanexor) in all NOTCH1-dependent T-ALL cell lines.	Eltanexor	62-71	notch receptor 1	Homo sapiens	80-86
35489384-5	2022	In vitro treatment of TCL cell lines with KPT-8602, the second-generation selective inhibitor of nuclear export (SINE), inhibited XPO1 expression and showed significant anti-proliferative, cell-cycle arrest and pro-apoptotic efficacy.	Eltanexor	42-50	exportin 1	Homo sapiens	130-134
34206543-3	2021	We also showed that a selective inhibitor of nuclear export (SINE) selinexor and second generation eltanexor (KPT-8602) could suppress mCRPC growth, reduce androgen receptor (AR), and re-sensitize to androgen deprivation therapy.	Eltanexor	99-108	androgen receptor	Homo sapiens	156-173
34206543-3	2021	We also showed that a selective inhibitor of nuclear export (SINE) selinexor and second generation eltanexor (KPT-8602) could suppress mCRPC growth, reduce androgen receptor (AR), and re-sensitize to androgen deprivation therapy.	Eltanexor	99-108	androgen receptor	Homo sapiens	175-177
34206543-3	2021	We also showed that a selective inhibitor of nuclear export (SINE) selinexor and second generation eltanexor (KPT-8602) could suppress mCRPC growth, reduce androgen receptor (AR), and re-sensitize to androgen deprivation therapy.	Eltanexor	110-118	androgen receptor	Homo sapiens	156-173
34206543-3	2021	We also showed that a selective inhibitor of nuclear export (SINE) selinexor and second generation eltanexor (KPT-8602) could suppress mCRPC growth, reduce androgen receptor (AR), and re-sensitize to androgen deprivation therapy.	Eltanexor	110-118	androgen receptor	Homo sapiens	175-177
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	forkhead box O3	Homo sapiens	64-70
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	dynactin subunit 6	Homo sapiens	72-75
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	H3 histone pseudogene 16	Homo sapiens	77-80
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	NFKB inhibitor alpha	Homo sapiens	82-94
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	protein phosphatase 2 phosphatase activator	Homo sapiens	99-103
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	AKT serine/threonine kinase 1	Homo sapiens	133-136
35489384-6	2022	In mechanism, KPT-8602 restored the localization of cytoplasmic FOXO3A, p27, p21, IkappaBalpha and PP2A into the nucleus, leading to AKT and NF-kappaB deactivation.	Eltanexor	14-22	nuclear factor kappa B subunit 1	Homo sapiens	141-150
35367710-3	2022	Using the second-generation XPO1 inhibitor KPT-8602 as the lead compound, structure-based optimization provided D4 with high anti-proliferation efficacy (IC50 = 24 nM in MM.1S).	Eltanexor	43-51	exportin 1	Rattus norvegicus	28-32
32826328-0	2020	The XPO1 inhibitor KPT-8602 synergizes with dexamethasone in acute lymphoblastic leukemia.	Eltanexor	19-27	exportin 1	Homo sapiens	4-8
33887086-4	2021	Herein, we report clickable probes based on the XPO1 inhibitors selinexor and eltanexor for the labeling of XPO1 in live cells to assess target engagement and selectivity.	Eltanexor	78-87	exportin 1	Homo sapiens	108-112
33745946-6	2021	Administration of KPT-8602, an XPO1 inhibitor, followed by AZD-6738, an ATR inhibitor, resulted in dramatic antitumor effects and prolonged survival in TP53-mutant models of CRC.	Eltanexor	18-26	exportin 1	Homo sapiens	31-35
33745946-6	2021	Administration of KPT-8602, an XPO1 inhibitor, followed by AZD-6738, an ATR inhibitor, resulted in dramatic antitumor effects and prolonged survival in TP53-mutant models of CRC.	Eltanexor	18-26	tumor protein p53	Homo sapiens	152-156
34012430-0	2021	The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response.	Eltanexor	37-46	exportin 1	Homo sapiens	22-26
32826328-1	2020	PURPOSE: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells.	Eltanexor	9-17	exportin 1	Homo sapiens	53-63
32826328-1	2020	PURPOSE: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells.	Eltanexor	9-17	exportin 1	Homo sapiens	65-69
32826328-1	2020	PURPOSE: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells.	Eltanexor	19-28	exportin 1	Homo sapiens	53-63
32826328-1	2020	PURPOSE: KPT-8602 (Eltanexor) is a second generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in pre-clinical models and with minimal effects on normal cells.	Eltanexor	19-28	exportin 1	Homo sapiens	65-69
32826328-9	2020	CONCLUSION: Our pre-clinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1 and E2F mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.	Eltanexor	53-61	nuclear receptor subfamily 3 group C member 1	Homo sapiens	137-142
27211268-0	2017	KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.	Eltanexor	0-8	exportin 1	Homo sapiens	43-47
30563936-7	2019	RESULTS: JAK2V617F-mutant HEL, SET-2, and HEL cells resistant to JAK inhibition are exquisitely sensitive to RAN knockdown or pharmacologic inhibition by KPT-330 or KPT-8602.	Eltanexor	165-173	Janus kinase 2	Homo sapiens	9-13
30563936-7	2019	RESULTS: JAK2V617F-mutant HEL, SET-2, and HEL cells resistant to JAK inhibition are exquisitely sensitive to RAN knockdown or pharmacologic inhibition by KPT-330 or KPT-8602.	Eltanexor	165-173	RAN, member RAS oncogene family	Homo sapiens	109-112
29299164-7	2017	Studies comparing cytotoxicity and XPO1 occupancy in cell lines treated with selinexor or KPT-8602 indicated that XPO1 occupancy by both compounds could reach saturation regardless of drug sensitivity.	Eltanexor	90-98	exportin 1	Homo sapiens	35-39
29299164-7	2017	Studies comparing cytotoxicity and XPO1 occupancy in cell lines treated with selinexor or KPT-8602 indicated that XPO1 occupancy by both compounds could reach saturation regardless of drug sensitivity.	Eltanexor	90-98	exportin 1	Homo sapiens	114-118
27780859-0	2017	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.	Eltanexor	43-51	exportin 1	Homo sapiens	22-32
27211268-5	2017	Here we report the anti-leukemic efficacy and tolerability of KPT-8602, a second-generation XPO1 inhibitor.	Eltanexor	62-70	exportin 1	Homo sapiens	92-96